$4.46 Billion is the total value of NEA Management Company, LLC's 58 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 15.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| COUR | New | COURSERA INC | $952,060,000 | – | 21,156,891 | +100.0% | 21.37% | – |
| DM | DESKTOP METAL INC | $423,400,000 | -13.4% | 28,416,088 | 0.0% | 9.50% | -26.4% | |
| EAR | EARGO INC | $325,721,000 | +11.4% | 6,520,948 | 0.0% | 7.31% | -5.3% | |
| ALLK | ALLAKOS INC | $248,465,000 | -18.0% | 2,164,704 | 0.0% | 5.58% | -30.3% | |
| NET | CLOUDFLARE INC | $194,169,000 | -8.4% | 2,763,583 | 0.0% | 4.36% | -22.1% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $193,742,000 | -20.4% | 1,590,002 | 0.0% | 4.35% | -32.3% | |
| OPEN | OPENDOOR TECHNOLOGIES INC | $141,264,000 | -6.8% | 6,666,548 | 0.0% | 3.17% | -20.7% | |
| OYST | OYSTER PT PHARMA INC | $108,314,000 | -2.9% | 5,925,287 | 0.0% | 2.43% | -17.4% | |
| RYTM | RHYTHM PHARMACEUTICALS INC | $104,485,000 | -26.9% | 4,912,306 | 0.0% | 2.34% | -37.9% | |
| MILE | New | METROMILE INC | $96,564,000 | – | 9,384,295 | +100.0% | 2.17% | – |
| NKTX | NKARTA INC | $95,574,000 | -46.5% | 2,904,974 | 0.0% | 2.14% | -54.5% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCadr | $90,709,000 | -1.5% | 17,082,611 | 0.0% | 2.04% | -16.2% | |
| ARDX | ARDELYX INC | $90,254,000 | +2.3% | 13,633,582 | 0.0% | 2.03% | -13.0% | |
| SPT | Sell | SPROUT SOCIAL INC | $89,242,000 | -36.4% | 1,545,040 | -50.0% | 2.00% | -45.9% |
| BDTX | BLACK DIAMOND THERAPEUTICS INC | $83,693,000 | -24.3% | 3,449,845 | 0.0% | 1.88% | -35.6% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $83,002,000 | +13.5% | 4,187,801 | 0.0% | 1.86% | -3.5% | |
| UPST | UPSTART HLDGS INC | $73,860,000 | +216.2% | 573,184 | 0.0% | 1.66% | +168.7% | |
| ANNX | ANNEXON INC | $69,535,000 | +11.2% | 2,497,661 | 0.0% | 1.56% | -5.5% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $67,193,000 | -6.1% | 5,172,683 | 0.0% | 1.51% | -20.2% | |
| TRILLIUM THERAPEUTICS INC | $61,609,000 | -27.0% | 5,736,363 | 0.0% | 1.38% | -37.9% | ||
| AKUS | AKOUOS INC | $59,620,000 | -30.1% | 4,298,488 | 0.0% | 1.34% | -40.6% | |
| SVRA | New | SAVARA INC | $50,207,000 | – | 24,137,931 | +100.0% | 1.13% | – |
| INZY | INOZYME PHARMA INC | $48,399,000 | -4.1% | 2,444,379 | 0.0% | 1.09% | -18.5% | |
| CSPR | CASPER SLEEP INC | $45,077,000 | +17.7% | 6,226,130 | 0.0% | 1.01% | +0.1% | |
| AFMD | Sell | AFFIMED NV | $42,756,000 | +19.9% | 5,405,262 | -11.8% | 0.96% | +2.0% |
| VRNA | VERONA PHARMA PLCads | $42,708,000 | +19.4% | 5,108,563 | 0.0% | 0.96% | +1.6% | |
| GRTX | GALERA THERAPEUTICS INC | $38,482,000 | -13.8% | 4,362,986 | 0.0% | 0.86% | -26.7% | |
| BE | BLOOM ENERGY CORP | $36,067,000 | -5.6% | 1,333,333 | 0.0% | 0.81% | -19.7% | |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $34,725,000 | +91.2% | 16,302,596 | +74.2% | 0.78% | +62.6% |
| IMRA | IMARA INC | $33,905,000 | -61.7% | 4,017,170 | 0.0% | 0.76% | -67.5% | |
| MEIP | MEI PHARMA INC | $29,268,000 | +29.9% | 8,533,072 | 0.0% | 0.66% | +10.4% | |
| AVEO | AVEO PHARMACEUTICALS INC | $28,936,000 | +26.9% | 3,952,958 | 0.0% | 0.65% | +7.8% | |
| TCON | TRACON PHARMACEUTICALS INC | $28,535,000 | +603.4% | 346,718 | 0.0% | 0.64% | +498.1% | |
| GNCA | GENOCEA BIOSCIENCES INC | $28,121,000 | +12.0% | 10,376,936 | 0.0% | 0.63% | -4.8% | |
| GLYC | GLYCOMIMETICS INC | $27,358,000 | -19.9% | 9,089,041 | 0.0% | 0.61% | -31.9% | |
| MRKR | Buy | MARKER THERAPEUTICS INC | $24,000,000 | +231.0% | 10,714,285 | +114.3% | 0.54% | +182.2% |
| PHAS | PHASEBIO PHARMACEUTICALS INC | $22,987,000 | +3.0% | 6,643,704 | 0.0% | 0.52% | -12.4% | |
| GERN | GERON CORP | $21,269,000 | -0.6% | 13,461,538 | 0.0% | 0.48% | -15.6% | |
| CTIC | CTI BIOPHARMA CORP | $20,779,000 | -9.6% | 7,140,450 | 0.0% | 0.47% | -23.2% | |
| CSBR | CHAMPIONS ONCOLOGY INC | $19,365,000 | +4.7% | 1,713,720 | 0.0% | 0.44% | -10.9% | |
| MTCR | METACRINE INC | $18,990,000 | -21.1% | 3,062,977 | 0.0% | 0.43% | -33.0% | |
| XENE | XENON PHARMACEUTICALS INC | $17,759,000 | +16.4% | 992,107 | 0.0% | 0.40% | -1.0% | |
| STSA | New | SATSUMA PHARMACEUTICALS INC | $17,716,000 | – | 2,997,682 | +100.0% | 0.40% | – |
| TRVI | TREVI THERAPEUTICS INC | $16,100,000 | +12.0% | 5,940,796 | 0.0% | 0.36% | -5.0% | |
| IVA | INVENTIVA SAads | $15,312,000 | +1.4% | 1,041,666 | 0.0% | 0.34% | -13.8% | |
| SYBX | SYNLOGIC INC | $15,141,000 | +65.7% | 4,229,410 | 0.0% | 0.34% | +41.1% | |
| OBSV | OBSEVA SA | $14,906,000 | +56.2% | 4,586,563 | 0.0% | 0.34% | +32.9% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $13,984,000 | +71.6% | 2,382,286 | 0.0% | 0.31% | +46.0% | |
| SBBP | STRONGBRIDGE BIOPHARMA PLC | $11,430,000 | +13.6% | 4,141,308 | 0.0% | 0.26% | -3.4% | |
| RGLS | REGULUS THERAPEUTICS INC | $10,064,000 | +15.6% | 6,451,056 | 0.0% | 0.23% | -1.7% | |
| TRVN | TREVENA INC | $6,823,000 | -16.4% | 3,811,691 | 0.0% | 0.15% | -28.8% | |
| LQDA | LIQUIDIA TECHNOLOGIES INC | $6,688,000 | -8.8% | 2,486,062 | 0.0% | 0.15% | -22.7% | |
| LUMO | LUMOS PHARMA INC | $6,162,000 | -67.2% | 526,663 | 0.0% | 0.14% | -72.2% | |
| ERYP | ERYTECH PHARMA SAadr | $4,400,000 | -23.7% | 625,000 | 0.0% | 0.10% | -34.9% | |
| MLND | MILLENDO THERAPEUTICS INC | $2,120,000 | -43.9% | 1,766,779 | 0.0% | 0.05% | -52.0% | |
| AKTX | AKARI THERAPEUTICS PLCadr | $1,194,000 | +42.7% | 452,167 | 0.0% | 0.03% | +22.7% | |
| DZSI | Sell | DZS INC | $598,000 | -96.0% | 38,470 | -96.0% | 0.01% | -96.7% |
| VIRX | New | VIRACTA THERAPEUTICS INC | $343,000 | – | 37,093 | +100.0% | 0.01% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -129,827 | -100.0% | -0.01% | – |
| PLTR | Exit | PALANTIR TECHNOLOGIES INCcl a | $0 | – | -59,980 | -100.0% | -0.04% | – |
| SENS | Exit | SENSEONICS HOLDINGS INC | $0 | – | -11,464,235 | -100.0% | -0.26% | – |
| PANW | Exit | PALO ALTO NETWORKS INC | $0 | – | -268,684 | -100.0% | -2.52% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.